Sugi Predict

Sugi Predict / Compounds / SCHEMBL11943595

SCHEMBL11943595

SCHEMBL11943595

CCOCCCNc1c(N2CCN(S(=O)(=O)Cc3ccccc3)[C@@H](C)C2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.41
▸ ALDH1A1 P00352 4/20 0.36
▸ DCTPP1 Q9H773 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMYD3 Q9H7B4 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.34
▸ CHRM4 P08173 3/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ PKM P14618 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ USP2 O75604 1/20 0.33
▸ NSD2 O96028 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943612 0.89 MAPT (0.41) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943617 0.88 MAPT (0.40) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943192 0.87 MAPT (0.54) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943596 0.85 GCKR (0.41) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943597 0.83 MAPT (0.36) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943587 0.82 DCTPP1 (0.38) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943532 0.81 MAPT (0.43) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL13304479 0.80 SMN1; SMN2 (0.55) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943296 0.79 MAPT (0.53) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943973 0.78 MAPT (0.42) MAPTALDH1A1DCTPP1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885DCTPP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.